

Study of fixed dose combination pattern in rural hospital, Jammu

Shallini Gupta¹, Niraj Kumar², Vikram Gupta³, Sanjeev Kumar⁴

{¹Assistant Professor, Department of Pharmacology} {²Assistant Professor, Department of Pediatrics} Government Medical College, Doda, J & K, INDIA.

³Consultant Pediatrics, ⁴Consultant Surgery, CHC Akhnoor, J & K, INDIA.

Email: nirajkdr@gmail.com

Abstract

Background: Fixed dose combinations (FDCs) have different focal points and drawbacks. In nations like India there are various silly medicines as highlighted by the later prohibiting of FDCs in October 2018. Considering the medicine design makes a difference in creating national database which can be utilized to advance judicious use of drugs. **Method:** Outdoor Patient Department (OPD) prescriptions from various departments during the study period were used for the study. The drugs were classified according to Anatomical Therapeutic Chemical (ATC) classification. The whole data was described in percentage in table 1 and table 2. **Results:** The highest percentage of FDCs was seen in alimentary tract (37.5%), followed by anti infective(16.25%). Among the alimentary drugs maximum number was of antacid combination (26.6%) followed by combination of proton pump inhibitors and prokinetic drugs (Pantop D). In anti-infective group mostly included amoxiclav, norfloxacin-tinidazole, ofloxacin-ornidazole (46.15%). **Conclusion:** A multistep approach at different levels can curb the problems being faced by irrational FDCs prescribed in rural areas.

Key Words: Fixed dose combination, prescribing pattern, irrational, ATC classification.

*Address for Correspondence:

Dr Niraj Kumar, Assistant Professor, Department of Pediatrics, Government Medical College, Doda, J & K, INDIA.

Email: nirajkdr@gmail.com

Received Date: 03/09/2020 Revised Date: 23/10/2020 Accepted Date: 10/11/2020

DOI: <https://doi.org/10.26611/10101633>

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. 

Access this article online

| | |
|---|--|
| Quick Response Code: | Website: www.medpulse.in |
|  | Accessed Date: 22 December 2020 |

INTRODUCTION

Combination of two or more active ingredients in a fixed ratio is known as Fixed dose combination (FDC). It can be given as a sole agent given together or as a combined pharmaceutical product¹. Various advantages associated are synergistic action and increased efficacy (e.g. cotrimoxazole), adverse effects are less (e.g. levodopa with carbidopa, thiazides with potassium sparing diuretics), less pill burden and hence better patient compliance (e.g. anti-tubercular drug combinations). Disadvantages are also

there like incompatible pharmacokinetics, inflexible dose ratio, increased toxicity and cost, contraindication to one of the component. The FDC may not contain the specified amount of each individual medicine and the combination may not be synergistic. The most pressing concern with irrational FDCs is that they expose patients to unnecessary risk of adverse drug reactions². In spite of the fact that FDCs are accessible in nearly all helpful categories, numerous of them are unusual combinations. The categories having large number of FDCs are cough, cold and fever arrangements; analgesics and muscle relaxants; antimicrobials; drugs for hypertension, dyslipidemia, diabetes and psychiatric drug ranges; vitamins and minerals. The FDC detailing may have up to 5 or indeed more fixings with or without judiciousness of their nearness and within the quantity. Notwithstanding the basic principle of formulating FDC, the Indian medicine market has become the world leader of FDCs. The estimated number of FDCs in India is over 6000³. Time and again, studies, editorials have shown violation of scientific merits in having many FDCs without adequate

justification. Exploiting the liberal licensing system, many times bizarre FDCs find place. India today does not have the exact database of currently available FDCs in the market, their sales turnover and use pattern. The existence of unlimited brands of FDCs with different permutations and combinations leads to confusion rather than guiding the prescribing doctor. Many articles in print media and Non-Governmental Organizations addressed the levelheadedness of FDCs.

Drug controller of India (CDSCO) came out with the arrangement rules for the endorsement of FDCs in 2013⁴. CDSCO

has intermittently prohibited different FDCs due to reasons such as need of basis or prove and potential security concern. In 2007, the Drugs Control General of India (DCGI) issued proclamations to State licensing authorities (SLAs) to pull back 294 FDCs which were not endorsed by CDSCO.⁵

Despite these interventions, irrational FDCs are still available in the market and are used extensively. The interventions are not successful due to several reasons. One such reason relates to exporting of FDCs that are banned in a particular country to the neighboring countries⁶. In spite of these intercessions, unreasonable FDCs are still accessible within the advertise and are utilized extensively. So it is necessary to study the pattern of prescribing pattern of FDCs especially in rural hospitals as less data is available despite of high prescribing trends.

METHODS

A cross-sectional descriptive study was done for one year in CHC Akhnoor. Prescriptions from Out-patient departments especially Medicine and Pediatrics were collected and analysed. The data was entered, stored and evaluated using Microsoft excel 2016. Data was calculated according to the percentages. Institutional ethical clearance was taken.

OBSERVATIONS AND RESULTS

The data was entered, stored and evaluated using Microsoft excel 2016. Descriptive statistics was used to analyze data. The prescribed fixed dose combination drugs and other drugs were categorized according to Anatomical Therapeutic Chemical classification (ATC classification). The percentage of Fixed drug combinations used in each class and their contribution to overall Fixed drug combinations were calculated. Numbers of Fixed drug combinations that are currently banned were also identified. Most of the prescriptions were collected from department of Medicine and Pediatrics followed by Obs and Gynae, Surgery and other allied branches. Over 1000 prescriptions were collected and analysed. Out of these 1000 prescriptions about 2300 drugs were prescribed. Among these drugs, about 800 were FDCs, and rest 1500 were others. Most common FDCs in elderly age group belonged to Gastrointestinal system and in Pediatric population mainly respiratory system. The group wise distribution of drugs, according to ATC classification and FDCs in that category, is listed in the Table 1.

Table 1: ATC Class of drugs prescribed.

| S.no. | ATC classification | No. of FDCs | Percentage |
|-------|--------------------------------|-------------|------------|
| 1 | Alimentary tract | 300 | 37.5 |
| 2. | Blood and blood forming organs | 20 | 2.5 |
| 3. | CVS | 2 | 0.125 |
| 4. | Dermatology | 0 | 0 |
| 5. | Genitourinary | 70 | 8.75 |
| 6. | Systemic hormones | 8 | 1 |
| 7. | Anti infective | 130 | 16.25 |
| 8. | Musculoskeletal | 70 | 8.75 |
| 9. | Nervous | 90 | 11.25 |
| 10. | Anti parasitic | 8 | 1 |
| 11. | Respiratory system | 100 | 12.5 |
| 12. | Others | 3 | 3.75 |

The highest percentage of FDCs were seen in alimentary tract (37.5%), followed by anti infective (16.25%). The next high number was seen in respiratory system (12.5%) which was also high in pediatric population followed by nervous system(11.25%), then musculoskeletal (8.75%) and genitourinary (8.75%). It was followed by systemic hormones (1%) and antiparasitic (1%) then CVS (0.125%). Among the alimentary drugs maximum number was of antacid combination followed by combination of proton pump inhibitors and prokinetic drugs (Pantop D). In case of respiratory drugs maximum number was of antihistaminics, anticholinergics followed by antiasthmatics. In nervous system combination of paracetamol, tramadol followed by paracetamol, codeine and caffeine. In antiinfective group mostly amoxiclav, norfloxacin-tinidazole, ofloxacin-ornidazole. The ATC classification and various FDCs, their number and percentage is shown in table 2.

Table 2: ATC classification, no. of prescriptions and percentage

| S.no | ATC classification | Name of drugs | No. of prescriptions | %age |
|------|--------------------|------------------|----------------------|--------|
| 1. | Alimentary tract | Simethicone | 80 | 26.6% |
| | | Alum.hydroxide | | |
| | | Mag .hydroxide | | |
| | | Pantoprazole | 65 | 21.6% |
| 2. | Anti infective | Domperidone | | |
| | | Amoxiclav | 60 | 46.15% |
| | | Norfloxacin | 45 | 34.61% |
| 3. | Respiratory | Tinidazole | | |
| | | Pseudoephedrine | 40 | 40% |
| | | Guaifensin | | |
| | | Dextromethorphan | 30 | 30% |
| 4. | Nervous sytem | Phenylephrine | | |
| | | chlorphenarimine | | |
| | | Paracetamol | 35 | 38.89% |
| | | Tramadol | | |
| | | Paracetamol | 30 | 33.3% |
| | | Codeine | | |
| | | Caffeine | | |

DISCUSSION

The Indian pharmaceutical industry has ended up the world pioneer of FDCs and various considers have appeared infringement of logical merits

without satisfactory defense among accessible FDCs. There's no database of currently available FDCs within the showcase, their deals turnover and use pattern⁷. Polypharmacy is exceptionally common and there's an expanding slant to combine drugs, more regularly than not without a sound premise for doing so. As per the Rule 122E of Drugs and Cosmetics Act 1940, the FDCs are considered as New Drugs and the Central Drugs Standard Control Organization (CDSCO), after due examination of data on rationality, safety, and efficacy, issues approval. On the basis of this, the State Licensing Authority (SLA) gives the manufacturing and marketing permission. Incidentally, in the past, SLAs issued the license to manufacture and market without asking for no-objection from CDSCO. Thus, the efficacy, safety, and rationality of such FDCs remain questionable. This "disconnect" between the CDSCO and SLAs has precipitated a roadblock in the action against irrational FDCs. In September 16, 2014, Service of Wellbeing and Family Welfare (MOH and FW) constituted a committee for looking at the applications for soundness, security, and viability of the FDCs.[8] Based on discoveries of the master board, on Feb 10, 2016, 344 FDCs were precluded beneath Segment 26A of Drugs and Makeup Act, 1940.⁹ Authors have found that a total of 34.78% drugs were FDCs. A study conducted by Biswadeep das MD *et al.*, had 64.8% as FDCs which is high compared to our study.¹⁰ Highest number of FDCs belonged to alimentary system followed by drugs

belonging to anti-infective, Blood and blood forming organs and respiratory system. In a study done in various clinical departments by Deepak *et al.*, percentage of FDCs prescribed were 64.29% and most of them belonged to antimicrobial class¹¹. This study finds that FDCs constitute a significant portion of drugs that are prescribed in the department of OBG. Many of these drugs were recently banned combinations because of their irrationality¹². Wide scale studies on FDC usage in various clinical departments to help build national database may go long way in promoting rational drug use.

SUMMARY AND CONCLUSION

To control the unreasonable utilization of FDC in India, a multistep approach including all partners including customers, doctors, administrative specialist, industry and the academicians is required. The authorization instrument by the controllers has to be reinforced. Both the central and state controllers must harmonize their methods for permitting FDCs. Pharmacovigilance also plays an important role in curbing the irrational use of FDCs. A multipronged corrective approach involving regulator, academia, industry, physicians, and public is needed to correct the dismal FDC scenario in the country.

REFERENCES

1. World Health Organization. WHO Expert Committee on Specifications for Pharmaceutical Preparations. World Health Organ Tech Rep Sep 2005; 929:1-142.
2. Gautam CS, Saha L. Fixed dose drug combinations (FDCs): Rational or irrational: a view point. Bri J Clinical Pharmacol. 2018;65(5):795-6.

3. Gupta YK, Ramachandran SS. Fixed dose drug combinations: Issues and challenges in India. *Indian J Pharmacol.* 2016; 48:347-9.
4. CDSCO. Policy Guidelines for the Approval of Fixed Dose Combinations (FDCs) in India. 2013. Available from: <http://www.mohfw.nic.in/WriteReadData/1892s/6404452866Kokate%20Report.pdf>
5. CDSCO. Report of Expert Committee on Fixed Dose Combinations (FDCs) Licensed by SLAs for Manufacture without Approval of DCG (I), Applications of Which Received by CDSCO. 2015. Available from: <http://www.cdsc.nic.in/writereaddata/fdcexpert%2019.1.2016.pdf>
6. Shankar PR, Hassali MA, Shahwani NA, Iqbal Q, Anwar M, Saleem F. Responsible use of fixed-dose combination antibiotics in India. *Lancet Glob Health.* 2016 Oct 1; 4(10):e689.
7. Manjunatha C. H., Rohith V., Maheshwari R., Isabella Topno. Prescription Pattern of fixed dose drug combinations in obstetrics and gynecology department of a tertiary care hospital in Puducherry, India: an observational study. *International Journal of Basic and Clinical Pharmacology* . November 2018 ; 7 (11): 1-4
8. CDSCO. Department-Related Parliamentary Standing Committee on Health and Family Welfare Fifty-Ninth Report on the Functioning of the Central Drugs Standard Control Organization (CDSCO) 2012. [Last accessed on 2016 Jun 18]. Available from: <http://www.164.100.47.5/newcommittee/reports/englishcommittees/committee%20on%20health%20and%20family%20welfare/59.pdf>
9. CDSCO. Report of Expert Committee on Evaluation of Cases of Fixed Dose Combinations (FDCs) Considered as Irrational and Where Showcause Notices were Issued to the Applicants to Submit Their Replies. 2016. Available from: http://www.cdsc.nic.in/writereaddata/fdcreport10_2_2016.pdf .
10. Das B, Sarkar C, Datta A, Bohra S. A study of drug use during pregnancy in a teaching hospital in western Nepal. *Pharmacoepidemiol Drug Saf.* 2003;12(3):2215.
11. Upadhyay D, Singh A, Joshi H, Agarwal M, Katyal R. Study of Prescription Patterns of Fixed Dose Combinations Prescribed by Medical Interns. *IJBR* 2016; 7(9): 624-8.
12. The gazette of India. Available at: [http://egazette.nic.in/\(S\(03j4qcdv53fnnkbtre4tpsqq\)\)/EnhancedSearch.aspx](http://egazette.nic.in/(S(03j4qcdv53fnnkbtre4tpsqq))/EnhancedSearch.aspx). Accessed 16 October 2018.

Source of Support: None Declared
Conflict of Interest: None Declared